Not quite there...but close
These stocks do not have an FN rating, but we want to keep an eye on them. We outline the reasons below.
Watch list companies are not updated as frequently as our Biotech Stock Pick companies.
FN Summary: Lead asset (CAP-1002) for DMD had very good results in a small P2 trial. Company will initiate a 65 patient P3 trial, hopefully starting in by end of Q1 2022. Good cash position, but will not last long without a partner, which management says is required before starting P3. No recent insider buying on the open market.